Projects
Trials@Home
A consortium exploring the opportunities of moving clinical trials from the traditional clinic setting to the participant's immediate surroundings
Trials@Home aims to explore the potential of digital technologies for use in ‘remote decentralised clinical trials’ (RDCTs). The aim is to develop and test methods to streamline data collection as well as patient recruitment and retention.
€ 40,6 M
funding from IMI and EFPIA
31
partners
About the Trials@Home project
In a conventional clinical trial, patients have to make regular trips to the clinic for check-ups to monitor their condition. Many patients are understandably put off by the distance to the clinic and how often they would be expected to make the trip, and many patients who initially join trials drop out for logistical reasons.
Trials@Home aims to explore the potential of digital technologies for use in ‘remote decentralised clinical trials’ (RDCTs). They will develop and test methods to streamline data collection as well as patient recruitment and retention.
If successful, RDCTs could make it easier to recruit and retain larger numbers of patients, including people from groups that are often under-represented in trials. Furthermore, as data collection would be more or less continuous, the results would be more reliable and more representative of the real world.
If you would like to find out more, visit the Trials@Home website.
Trials@Home ambitions
- Defining the best practices for the conduct of RDCTs.
- Identifying technologies and other operational innovative approaches for RDCTs and selecting the appropriate technology package to be used for the pan-EU pilot.
- Designing and running a pan-EU pilot, comparing the scientific and operational quality of the RDCT with traditional trial approaches and evaluating the feasibility of the RDCT.
- Identifying, mapping and analysing the relevant ethical, quality, regulatory, legal and organisational barriers and enablers of RDCTs.
- Consulting with stakeholders and promoting the outcomes from the Trials@Home consortium through targeted communication, dissemination and training activities.
- Providing recommendations with supporting tools for implementing RDCTs in Europe and contributing to the update of ICH guidelines on RDCTs.
Lygature in Trials@Home
Providing expertise (a dedicated platform) to internal project communication) and various important deliverables like the Data management Plan, the Sustainability plan etc.
- Internal Project Communication. Lygature is responsible for delivering and maintaining the proprietary “MyProjectPlaza” communication platform. This ensures transparency, efficient clarification and fine-tuning among partners.
- Data management and other plans. Lygature supports delivering the Data Management Plan, the Project Sustainability plan etc. The DMP will contain key instruments for an effective storage and (re-)use of all generated data.
Lygature together with
Allergan, AstraZeneca, Bayer, Boehringer Ingelheim, CERTH-I, Covance, DREEM, eCLINICALHEALTH, FISABIO, IDF Europe, IQVIA, Janssen, JOANNEUM, Julius Clinical, Medlaw, Medtronic, MRN, Novartis, Pfizer, Sanofi, Syddansk Universitet, Takeda, Teva Pharmaceutical Industries Limited, UCB, UMCU, University of Dundee, University of Oxford, University Utrecht, UPPMD, Vital Transformation.
Acknowledgement of support
The research leading to these results has received support from the EU/EFPIA Innovative Medicines Initiative [2] Joint Undertaking (H2020-JTI-IMI2) Trials@Home grant n° 831458.
Project updates
-
Trials@Home Annual Meeting
On November 2 and 3, Trials@Home organised, in virtual format, its major annual event. More than 150 public and private partners and stakeholders came together to move the project forward, contribute to the larger landscape, and improve the access to clinical trials for patients. The meeting was held over two days, chaired by Rick Grobbee, Kim Hawkins and Mira Zuidgeest, the Trials@Home overall project leads, and included work packages updates and a series of scientific sessions. In short: a great opportunity to listen, engage, and contribute to the discussion and plans.
-
Press Release: BIOCORP: AARDEX® Group and BIOCORP recruited by Trials@Home – Decentralized Clinical Trial Centre of Excellence
The AARDEX and BIOCORP teams are outstanding collaborators, who anticipate the nuances of interventional decentralized clinical trials. They go to great lengths to provide the Trials@Home consortium with technology that is the sine qua non for study participants requiring precise insulin dosing and compliance monitoring, combining BIOCORP’s pen injector add-on Mallya® with AARDEX® Group’s Software to improve adherence to medication in a Hybrid Phase IV Diabetes Study.
-
Trials@Home Semi-Annual Meeting
On June 7 and 8, nearly two and a half years since the kickoff meeting in Paris, Trials@Home hosted a hybrid event with more than 100 delegates from public and private partners and stakeholders coming together in Brussels/Anderlecht (44) and virtually (61).